The U.S. FDA typically announces its inspections at facilities located outside the U.S. – a courtesy not extended to domestic manufacturing sites. This is about to change per an agency press release ...

The U.S. FDA’s decision to phase out animal testing for INDs is driving a new market of alternative, nonanimal testing technologies like organoids and organs-on-a-chip, speakers at Bio Korea 2025 said ...

In April, biopharma transactions amounted to $12.8 billion, a sharp decline from March’s $29.48 billion. However, with $79.66 billion in deal value during the first four months of 2025, the sector has ...

As biopharma companies continue to roll out their first-quarter  earnings, Trump administration tariffs remain at the top of investors’ minds. While executives offer their various strategies to ...

Ahead Therapeutics SL has received positive feedback from the EMA on its way toward initiating regulatory toxicology studies for its lead program in myasthenia gravis. The feedback supports the ...

Individuals with autoimmune diseases affecting the thyroid can suffer eye complications in the form of Graves’ orbitopathy, in which inflammation in and around the orbit leads to eyelid retraction, ...

UTR Therapeutics Inc. has submitted an IND application to the FDA for UTRxM1-18, a novel therapeutic approach for targeting c-MYC-driven cancers. Pending approval, a first-in-human phase I trial is ...

Private biotechs in Switzerland raised CHF833 million (US$1.002 billion) in 2024, driving an overall increase in capital investment in the sector to $3 billion, up from $2.4 billion in 2023.

Co. Ltd. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a tyrosine-protein phosphatase non-receptor type 2 (PTPN2; ...

Individuals with cystic fibrosis show a notably higher rate of attention deficit hyperactivity disorder (ADHD) symptoms than the general population. This association points to a possible role of the ...

Aptevo Therapeutics Inc. is advancing APVO-711, its bispecific antibody targeting PD-L1 x CD40 that combines checkpoint inhibition with immune activation in a single molecule.

Claudin-6 (CLDN6) is a protein found in the tight junctions of epithelial cells to modulate their permeability and barrier function, among other actions.